Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Picaud, Laetitia ^a   Thibault, Benoît ^a   Mery, Eliane ^a   Ouali, Monia ^a   Martinez, Alejandra ^a   Delord, Jean Pierre ^a,b   Couderc, Bettina ^a,b   Ferron, Gwenael ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Anti adhesion membranes; Hyaluronic acid; Ovarian adenocarcinoma; Surgery

Indexed keywords

ACTIN; BIOMATERIAL; CARBOXYMETHYLCELLULOSE; FOCAL ADHESION KINASE; HERMES ANTIGEN; HYALURONIC ACID; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; CD44 PROTEIN, HUMAN; HYALURONAN-MEDIATED MOTILITY RECEPTOR; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BIODEGRADABLE IMPLANT; CANCER TRANSPLANTATION; EVALUATION STUDY; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TISSUE ADHESIONS; TUMOR CELL LINE;

ABSORBABLE IMPLANTS; ANIMALS; ANTIGENS, CD44; CARBOXYMETHYLCELLULOSE SODIUM; CELL LINE, TUMOR; CELL PROLIFERATION; EVALUATION STUDIES AS TOPIC; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; HYALURONIC ACID; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TISSUE ADHESIONS;

EID: 84899580668     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-40     Document Type: Article

References (38)

1. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel Resection. Baiocchi G, Cestari LA, Macedo MP, Oliveira RAR, Fukazawa EM, Faloppa CC, Kumagai LY, Badiglian-Filho L, Menezes ANO, Cunha IW, Soares FA, J Surg Oncol 2011 104 250 254 10.1002/jso.21940 21472733
2. Advanced ovarian cancer: criteria of resectability. Chéreau E, Ballester M, Rouzier R, Coutant C, Daraï E, Bull Cancer 2009 96 1189 1197 19919915
3. Pharmacological bases of intraperitoneal chemotherapy. Gladieff L, Chatelut E, Dalenc F, Ferron G, Bull Cancer 2009 96 1235 1242 19923051
4. Abdominal adhesions: current and novel therapies. Ward BC, Panitch A, J Surg Res 2011 165 91 111 10.1016/j.jss.2009.09.015 20036389
5. Seprafilm: a retrospective preliminary evaluation of the impact on short-term oncologic outcome in colorectal cancer. Oikonomakis I, Wexner SD, Gervaz P, You S-Y, Secic M, Giamundo P, Dis Colon Rectum 2002 45 1376 1380 10.1007/s10350-004-6428-1 12394438
6. Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Kusunoki M, Ikeuchi H, Yanagi H, Noda M, Tonouchi H, Mohri Y, Uchida K, Inoue Y, Kobayashi M, Miki C, Yamamura T, Surg Today 2005 35 940 945 10.1007/s00595-005- 3061-0 16249848
7. Seprafilm® adhesion barrier: (1) a review of preclinical, animal, and human investigational studies. Diamond MP, Burns EL, Accomando B, Mian S, Holmdahl L, Gynecol Surg 2012 9 237 245 10.1007/s10397-012-0741-9 22837732
8. Effects of a hyaluronan-based membrane (Seprafilm) on intraperitoneally disseminated human colon cancer cell growth in a nude mouse model. Hubbard SC, Burns JW, Dis Colon Rectum 2002 45 334 341 discussion 341-344 10.1007/s10350-004-6178-0 12068190
9. Sodium hyaluronate enhances colorectal tumour cell metastatic potential in vitro and in vivo. Tan B, Wang JH, Wu QD, Kirwan WO, Redmond HP, Br J Surg 2001 88 246 250 10.1046/j.1365-2168.2001.01664.x 11167875
10. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, Huang J-F, Neudecker BA, Wang F-S, Wang F-S, Turley EA, Naor D, Proc Natl Acad Sci U S A 2004 101 18081 18086 10.1073/pnas.0407378102 15596723
11. Extracellular matrix of ovarian tumors. Ricciardelli C, Rodgers RJ, Semin Reprod Med 2006 24 270 282 10.1055/s-2006-948556 16944424
12. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Hiltunen EL, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, Juhola M, Tammi R, Tammi M, Kosma VM, Cancer Res 2002 62 6410 6413 12438225
13. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, Kosma VM, Cancer Res 2000 60 150 155 10646867
14. Hyaluronan synthase expression in ovarian cancer. Yabushita H, Noguchi M, Kishida T, Fusano K, Noguchi Y, Itano N, Kimata K, Noguchi M, Oncol Rep 2004 12 739 743 15375493
15. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Kayastha S, Freedman AN, Piver MS, Mukkamalla J, Romero-Guittierez M, Werness BA, Clin Cancer Res 1999 5 1073 1076 10353740
16. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C, Cancer Res 1993 53 3830 3838 8339295
17. Hyaluronic acid secreted by mesothelial cells: a natural barrier to ovarian cancer cell adhesion. Jones LM, Gardner MJ, Catterall JB, Turner GA, Clin Exp Metastasis 1995 13 373 380 7641421
18. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Gardner MJ, Catterall JB, Jones LM, Turner GA, Clin Exp Metastasis 1996 14 325 334 10.1007/BF00123391 8878406
19. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Li C-Z, Liu B, Wen Z-Q, Li H-Y, Folia Biol (Praha) 2008 54 180 186 19393131
20. The role of hyaluronan in mesothelium-induced motility of ovarian carcinoma cells. Carpenter PM, Dao AV, Anticancer Res 2003 23 3985 3990 14666707
21. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. Bourguignon LY, Zhu H, Shao L, Chen YW, J Biol Chem 2001 276 7327 7336 10.1074/jbc.M006498200 11084024
22. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. Bourguignon LY, Peyrollier K, Gilad E, Brightman A, J Biol Chem 2007 282 1265 1280 10.1074/jbc.M604672200 17092940
23. Utilization and safety of sodium hyaluronate-carboxymethylcellulose adhesion barrier. Bashir S, Ananth CV, Lewin SN, Burke WM, Lu Y-S, Neugut AI, Herzog TJ, Hershman DL, Wright JD, Dis Colon Rectum 2013 56 1174 1184 10.1097/DCR.0b013e31829ec889 24022535
24. Antiadhesive effect and safety of sodium hyaluronate-carboxymethyl cellulose membrane in thyroid surgery. Bae DS, Woo J-W, Paek SH, Kwon H, Chai YJ, Kim S-J, Choi JY, Lee KE, Youn Y-K, J Korean Surg Soc 2013 85 199 204 10.4174/jkss.2013.85.5.199 24266009
25. Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers. Leitao MM Jr, Byrum GV 3rd, Abu-Rustum NR, Brown CL, Chi DS, Sonoda Y, Levine DA, Gardner GJ, Barakat RR, Gynecol Oncol 2010 119 208 211 10.1016/j.ygyno.2010.07.027 20708225
26. Efficacy of a sodium hyaluronate-carboxycellulose membrane (seprafilm) for reducing the risk of early postoperative small bowel obstruction in patients with gynecologic malignancies. Tabata T, Kihira T, Shiozaki T, Tanida K, Kondo E, Nagao K, Okugawa T, Sagawa N, Int J Gynecol Cancer 2010 20 188 193 10.1111/IGC.0b013e3181c7fe84 20130522
27. The use of sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier in gynecologic malignancies: a retrospective review of outcomes. Tan A, Argenta P, Ramirez R, Bliss R, Geller M, Ann Surg Oncol 2009 16 499 505 10.1245/s10434-008-0235-1 19018596
28. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Bristow RE, Montz FJ, Gynecol Oncol 2005 99 301 308 10.1016/j.ygyno.2005.06.057 16085295
29. Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Peeler ST, Gynecol Oncol 2007 104 739 746 10.1016/j.ygyno.2006.09.029 17097723
30. Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers. Krill LS, Ueda SM, Gerardi M, Bristow RE, Gynecol Oncol 2011 120 220 223 10.1016/j.ygyno.2010.10.037 21145096
31. Postoperative peritoneal dissemination of ovarian cancer cells is not promoted by carbon-dioxide pneumoperitoneum at low intraperitoneal pressure in a syngenic mouse laparoscopic model with controlled respiratory support: a pilot study. Bourdel N, Matsuzaki S, Bazin J-E, Darcha C, Pouly J-L, Mage G, Canis M, J Minim Invasive Gynecol 2008 15 321 326 10.1016/j.jmig.2008.02.004 18439505
32. Protection of trocar sites from gallbladder cancer implantation by sodium hyaluronate carboxymethylcellulose-based bioresorbable membrane (Seprafilm) in a murine model [corrected]. Sasaki T, Shimura H, Tanaka T, Nakashima K, Matsuo K, Ikeda S, Surg Endosc 2004 18 246 251 10.1007/s00464-003-8128-7 14691710
33. Effect of antiadhesive agents on peritoneal carcinomatosis in an experimental model. Pucciarelli S, Codello L, Rosato A, Del Bianco P, Vecchiato G, Lise M, Br J Surg 2003 90 66 71 10.1002/bjs.4006 12520577
34. Hyaluronan-CD44 interactions as potential targets for cancer therapy. Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S, FEBS J 2011 278 1429 1443 10.1111/j.1742-4658.2011.08071.x 21362138
35. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK, Ricciardelli C, Clin Exp Metastasis 2011 28 113 125 10.1007/s10585-010-9363-7 21153687
36. Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. Kouvidi K, Berdiaki A, Nikitovic D, Katonis P, Afratis N, Hascall VC, Karamanos NK, Tzanakakis GN, J Biol Chem 2011 286 38509 38520 10.1074/jbc.M111.275875 21914806
37. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, Landsman-Milo D, Bremer MGEG, Moghimi SM, Peer D, J Control Release 2011 156 231 238 10.1016/j.jconrel.2011.06.031 21745506
38. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Thibault B, Castells M, Delord J-P, Couderc B, Cancer Metastasis Rev 2013 doi:10.1007/s10555-013-9456-2.